« Zurück
Startseite /
Pyrrolidinedithiocarbamate (ammonium)

Pyrrolidinedithiocarbamate (ammonium)

ArtNr	HY-18738-500mg
Hersteller	MedChem Express
CAS-Nr.	5108-96-3
Menge	500 mg
Kategorie	Neuroscience Neuroinflammation Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Németh ZH, et al. Pyrrolidinedithiocarbamate inhibits NF-kappaB activation and IL-8 production in intestinal epithelial cells. Immunol Lett. 2003 Jan 2;85(1):41-6.\|[2]Qin JD, et al. Effect of ammonium pyrrolidine dithiocarbamate (PDTC) on NF-κB activation and CYP2E1 content of rats with immunological liver injury. Pharm Biol. 2014 Nov;52(11):1460-1466. Acta Pharm Sin B. 2022 Sep;12(9):3618-3638. Acta Pharm Sin B. 2025 Mar;15(3):1535-1551. Acta Pharmacol Sin. 2023 Aug;44(8):1712-1724. Acta Pharmacol Sin. 2025 Aug;46(8):2163-2179. Am J Cancer Res. 2023 Feb 15;13(2):419-435. Am J Transl Res. 2018 Dec 15;10(12):4247-4257. Andrology. 2023 Mar;11(3):575-590. Ann Hepatol. 2024 Mar-Apr;29(2):101279. Antivir Res. 2023 Feb 20;105559. Aquaculture. 2025 Sep 15. Arch Biochem Biophys. 2020 Feb 15;680:108242. Biochim Biophys Acta Mol Basis Dis. 2023 Oct;1869(7):166819. Biomed Pharmacother. 2019 Dec;120:109527. bioRxiv. 2025 Aug 13:2025.08.11.669793. BMC Microbiol. 2019 Jul 29;19(1):170. Brain Behav Immun Health. 2022 Oct 29:26:100546. Brain Behav Immun. 2020 Nov;90:108-137. Brain Behav Immun. 2025 Oct:129:801-817. Brain Res Bull. 2021 Dec:177:22-30. Cancers (Basel). 2023 Mar 6;15(5):1624. Cell Death Dis. 2021 Jan 11;12(1):67. Cell Death Dis. 2025 Apr 26;16(1):346. Cell Death Dis. 2019 Feb 8;10(2):113. Cell Rep Med. 2024 May 16:101580. Cell Rep Med. 2025 Jan 16:101922. Cell Signal. 2021 Nov:87:110137. Cell Signal. 2024 Sep 18:111427. Chem Biol Interact. 2022 Sep 25:365:110068. Clin Transl Med. 2022 Jun;12(6):e850. Cytokine. 2023 Feb:162:156086. Dev Cell. 2025 Jun 23;60(12):1751-1767.e9. Diabetes. 2024 Jun 13:db230969. Dig Dis Sci. 2025 Aug 5. EBioMedicine. 2024 Sep 16:108:105344. EMBO Rep. 2021 Jul 5;22(7):e51678. Evid Based Complement Alternat Med. 2021 Apr 1:2021:6662261. Exp Biol Med. 2023 Feb;248(4):293-301. Exp Eye Res. 2021 Apr:205:108507. Eye Vis (Lond). 2022 Sep 5;9(1):35. FEBS Lett. 2021 Oct;595(19):2447-2462. Food Biosci. 2021, 101268. Front Cell Dev Biol. 2021 Feb 11:9:570451. Gut Microbes. 2024 Jan-Dec;16(1):2313769. Heliyon. 2023 Nov 20;9(12):e22599. Hum Cell. 2023 Nov;36(6):1928-1937. Inflammation. 2020 Jun;43(3):916-936. Inflammation. 2021 Aug;44(4):1581-1591. Int Immunopharmacol. 2019 May:70:28-36. Int Immunopharmacol. 2020 Jan;78:106043. Int Immunopharmacol. 2021 Jul:96:107779. Int Immunopharmacol. 2023 Aug:121:110433. Int Immunopharmacol. 2024 Sep 19;142(Pt B):113151. Int Immunopharmacol. 2025 Aug 29:165:115451. Int J Biol Macromol. 2022 Oct 21;S0141-8130(22)02401-1. Int J Biol Sci. 2019 Jan 24;15(3):688-700. Int J Biol Sci. 2025 Aug 11;21(12):5206-5222. Int J Mol Sci. 2020 Dec 23;22(1):60. Int J Mol Sci. 2021 Nov 11;22(22):12188. Int J Mol Sci. 2023 Jul 11;24(14):11331. Int J Oncol. 2020 Jan;56(1):101-112. Int J Pharm. 2022 Nov 25:628:122361. J Alzheimers Dis. 2022;85(1):167-178. J Cell Physiol. 2019 Aug;234(10):18731-18747. J Cell Physiol. 2019 Dec;234(12):23302-23314. J Dairy Sci. 2023 Feb;106(2):1315-1329. J Dairy Sci. 2024 Jul 19:S0022-0302(24)01027-0. J Dairy Sci. 2025 Mar;108(3):2152-2168. J Ethnopharmacol. 2023 Sep 15:313:116533. J Exp Med. 2020 Jul 6;217(7):e20192083. J Headache Pain. 2024 Jan 5;25(1):3. J Headache Pain. 2025 May 1;26(1):97. J Inflamm Res. 2021 Mar 5;14:719-735. J Inflamm Res. 2021 Oct 5;14:5079-5094. J Integr Neurosci. 2025 Jun 23;24(6):38100. J Nanobiotechnology. 2025 Jul 5;23(1):488. J Nat Prod. 2021 Apr 23;84(4):1022-1033. J Neuroinflammation. 2021 Jun 28;18(1):146. J Periodontal Res. 2024 Feb;59(1):140-150. J Periodontol. 2025 Mar;96(3):255-267. J Transl Med. 2025 Nov 13;23(1):1278. J Virol. 2025 Aug 19;99(8):e0065525. JACC Basic Transl Sci. 2022 Aug 3;7(8):820-840. Lasers Med Sci. 2023 Oct 18;38(1):240. Life Sci. 2025 Apr 23:123663. Life Sci. 2025 Aug 22:380:123926. Liver Int. 2022 Dec;42(12):2724-2742. Mediators Inflamm. 2020 Jul 24;2020:8298615. Microb Pathog. 2025 Apr 10:107559. Microbiome. 2023 Jan 31;11(1):17. Microorganisms. 2021 Sep 17;9(9):1983. Mil Med Res. 2023 Nov 25;10(1):56. Mol Immunol. 2022 Dec:152:67-77. Mol Med Rep. 2020 Nov;22(5):4227-4235. Mol Med. 2021 Dec 11;27(1):156. Mol Med. 2023 Aug 21;29(1):113. Mol Neurobiol. 2021 Aug;58(8):3848-3862. Mol Neurobiol. 2022 Nov;59(11):6903-6917. Nat Commun. 2024 Jan 10;15(1):449. Nat Commun. 2024 Sep 12;15(1):7996. Nat Commun. 2025 May 27;16(1):4887. Neuropharmacology. 2025 Nov 15:279:110638. Oncogene. 2022 Mar;41(13):1866-1881. Oncoimmunology. 2018 Aug 23;7(11):e1461303. Oncotarget. 2020 Feb;39(7):1414-1428. Oxid Med Cell Longev. 2017:2017:3869561. Oxid Med Cell Longev. 2021 Mar 29:2021:6678276. Parasit Vectors. 2020 Aug 31;13(1):435. Pathol Res Pract. 2025 Oct 17;276:156273. Pharmaceuticals (Basel). 2025 Jun 20;18(7):934. Pharmacol Res. 2018 Jul:133:218-235. Phytomedicine. 2022 Sep:104:154290. Phytomedicine. 2025 Sep:145:157009. Phytother Res. 2023 Oct;37(10):4771-4790. PPAR Res. 2021 Aug 25:2021:6086265. Redox Biol. 2021 Oct;46:102098. Res Sq. 2025 Mar 16. Research Square Preprint. 2021 Jan. Research Square Preprint. 2021 Jul. Research Square Preprint. 2023 Dec 1. Research Square Preprint. 2023 Jul 25. Research Square Preprint. July 21st, 2022. Research Square Print. 2022 Aug. Research Square Print. 2022 Jun. Research Square Print. December 14th, 2022. Sci Adv. 2025 Aug;11(31):eadu4270. Sci Rep. 2024 Nov 4;14(1):26583. Sci Total Environ. 2024 Jul 30:949:175139. Sci Total Environ. 2024 May 10:933:173079. Signal Transduct Target Ther. 2023 Mar 15;8(1):107. SSRN. 2024 Jan 9. Theranostics. 2021 Jan 19;11(7):3392-3416. Vaccines. 2019 Dec 14;7(4):216. Vet Parasitol. 2022 May;305:109710. Vet Res. 2024 Jul 29;55(1):93. Vet Sci. 2024 May 8;11(5):204. Exp Neurol. 2024 Jul:377:114794. Sci Transl Med. 2025 May 7;17(797):eads2694.
Smiles	SC(N1CCCC1)=S.N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Ammonium pyrrolidinedithiocarbamate,PDTC (ammonium),APDC
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound1
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - HS Code	H315, H319
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Product Description	Pyrrolidinedithiocarbamate ammonium (Ammonium pyrrolidinedithiocarbamate) is a selective and blood-brain barrier (BBB) permeable NF-κB inhibitor.
Manufacturer - Research Area	Inflammation/Immunology; Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)\|H2O : 50 mg/mL (ultrasonic)
Manufacturer - Pathway	NF-κB
Clinical information	Phase 3
Isoform	NF-κB
UNSPSC Code	12352005
Precautionary	H315, H319

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.